MKMadoka Kuramitsu

Madoka Kuramitsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Madoka Kuramitsu has a total of 218 co-authors. Here are the top co-authors by number of shared publications:

  • Takuo Mizukami

    Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases , Tokyo

    11 shared publications
  • Isao Hamaguchi

    Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan

    10 shared publications
  • Haruka Momose

    Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases , Tokyo, Japan

    9 shared publications
  • Isao Hamaguchi

    Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Tokyo, Japan; Department of Clinical Laboratory, Subaru Health Insurance Society Ota Memorial Hospital, Gunma, Japan

    8 shared publications
  • Kazu Okuma

    Department of Microbiology, Faculty of Medicine, Kansai Medical University, Osaka, Japan

    8 shared publications
  • Kazunari Yamaguchi

    Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan

    8 shared publications

Latest Publications

  • Open Access

    Global overview and regional protocols for molecular diagnosis of human T-cell lymphotropic virus

    by Philippa A. S. Hetzel, Aileen Rowan, Tatiane Assone, Nick Vandegraaff, Graham Taylor, Daniel Bradshaw, Carolina Rosadas, Tomoo Sato, Yoshihisa Yamano, Madoka Kuramitsu, et al.

    Human T-cell lymphotropic virus type-1 (HTLV-1) has been recognized as an infection of global importance by the World Health Organization (WHO) in their published HIV, Hepatitis, and STI Global Health Sector Strategy 2022-2030 ; however, there are no commercial molecular assays for HTLV-1 available globally. While some countries are strengthening their efforts to diagnose HTLV-1 and prevent transmission (i.e., Brazil introduced universal antenatal screening in 2024), the prevalence of HTLV-1 in many parts of the world is unknown. Unsurprisingly, there is great inequity in access to molecular HTLV testing services, which can importantly contribute both as part of a diagnostic confirmatory testing algorithm and be used to monitor disease. Due to the lack of commercially available molecular assays, laboratories rely on in-house developed protocols, resulting in substantial variability in methodologies and access to testing. An HTLV Testing Working Group was established by the International Retrovirology Association in 2023 with the objective to improve access to and the quality of molecular testing for HTLV-1 globally. Representatives from nine laboratories in Argentina, Australia, Brazil, Iran, Japan, Sweden, and the United Kingdom have collaboratively compared their in-house molecular protocols. The methods are presented and summarized with a discussion of the relative strengths and limitations of each platform and key considerations for laboratories establishing molecular HTLV testing capacity. This analysis provides a practical framework supporting equitable expansion of HTLV molecular diagnostics globally, aiming to help countries with varying access to funding to be able to select the assay best suited to their means while recognizing the relative risks and benefits.

  • Open Access

    Molecular Evidence of Human T‑Cell Leukemia Virus Type 1 Transmission by Needlestick Injury in Healthcare Workers

    by Masahito Tokunaga, Madoka Kuramitsu, Masumichi Saito, Miyuki Yoshimori, Jun Odawara, Yoshikiyo Ito, Hitomi Nakamura, Yasuko Sagara, Mieko Ishii, Naomi Nojiri, et al.

    Human T‑cell leukemia virus type 1 (HTLV‑1) is a retrovirus that spreads primarily through cell‐to‐cell transmission. Occupational transmission of HTLV‐1 by needlestick injury is considered exceedingly rare, with no reported molecularly confirmed cases. We report two healthcare workers who experienced accidental needlestick injuries while caring for patients seropositive for HTLV‑1 and subsequently seroconverted. Full‑length HTLV‑1 proviral sequencing revealed complete nucleotide identity between source patients and infected nurses. These strains belonged to the HTLV‐1 subtype 1a Japanese subgroup but were distinct from 315 previously registered strains. Proviral integration site analysis demonstrated nonoverlapping integration profiles between source patients and healthcare workers, providing direct evidence of de novo HTLV‑1 infection rather than expansion of transferred infected cells. Longitudinal analysis in one case showed dynamic clonal turnover between 5 and 14 months after transmission; > 90% of infected‐cell clones were replaced, although the proviral load remained stable and low. Serological profiling revealed transiently elevated immunoglobulin M responses to Gag p19 peptides during early infection, followed by gradual immunoglobulin G maturation. These findings provide the first molecular confirmation of HTLV‑1 transmission via needlestick injury resulting in de novo infection, revealing an under‐recognized occupational exposure route and supporting reconsideration of post‐exposure testing strategies, particularly in endemic regions.

  • Identification of Occult Simian T-Cell Leukemia Virus Type 1 Infection in Japanese Macaques

    by Maureen Kidiga, Megumi Murata, Poonam Grover, Hirotaka Ode, Yasumasa Iwatani, Yohei Seki, Madoka Kuramitsu, Mayumi Morimoto, Takayoshi Natsume, Akihisa Kaneko, et al.

    Background: Primate T-cell leukemia virus type 1 (PTLV-1), classified into the genus Deltaretrovirus, persists in infected primates and can lead to adult T-cell leukemia and inflammatory diseases. Unlike hepatitis viruses, it remains unclear whether PTLV-1 could cause occult infection, a rare latent infection status characterized by detectable provirus without accompanying antibody responses. Methods: A longitudinal study was conducted to characterize mother-to-child transmission of simian T-cell leukemia virus type 1 (STLV-1) in Japanese macaques (JMs). Stored blood samples obtained from STLV-1–infected JM mothers and their offspring were analyzed for proviral loads, antiviral antibody titers, proviral DNA sequencing, transcriptional capability, and clonality of the infected cells. Results: One JM infant was found to be positive for proviral DNA without detectable anti-STLV-1 antibodies. The seronegative infection persisted for at least 5 years, despite positive antibody responses to other viruses that are widespread in JMs. Further analyses of the infant's blood demonstrated that (1) the provirus had no defective mutations, (2) tax messenger RNA expression could be induced by in vitro culture, and (3) substantial numbers of heterogeneous clones of STLV-1–infected cells were undergoing sequential turnover. In an additional retrospective study of a large JM cohort, 3 of 38 offspring of STLV-1–infected mothers were found to be persistently infected with STLV-1 without seroconversion. Conclusions: Our findings demonstrate that maternal STLV-1 transmission can occasionally persist for years without seroconversion. This represents the first discovery of occult infection in the genus Deltaretrovirus.


  • Identification of Natural Remission of Mother-to-Child Retroviral Transmission

    by Poonam Grover, Megumi Murata, Maureen Kidiga, Sakura Hayashi, Hirotaka Ode, Yasumasa Iwatani, Mayumi Morimoto, Takayoshi Natsume, Akihisa Kaneko, Jun-Ichirou Yasunaga, et al.

    Background: Spontaneous remission once a retroviral infection has been established does not occur and infection persists lifelong. Methods: Stored blood samples obtained from simian T-cell leukemia virus type 1 (STLV-1)-infected Japanese macaque (JM; Macaca fuscata) mothers and their offspring during long-term follow-up as well as periodic health checkups were analyzed for proviral DNA levels, anti-STLV-1 antibody titer, DNA sequence, and viral clonality in peripheral blood mononuclear cells. Results: We found spontaneous remission after the establishment of retrovirus mother-to-child transmission (MTCT); 3 JM infants were positive for the provirus at 5 and 8 months of age; however, no evidence of persistent STLV-1 infection was found in any of these infants thereafter up to 3 years of age. The viral env sequencing showed the presence of signature nucleotide polymorphisms, which were identical between each mother and infant but not others, suggesting STLV-1 MTCT. STLV-1–infected cells were capable of viral transmission and were composed of a heterogeneous population of clones, which were completely replaced between 5 and 8 months of age, suggesting the possibility of ongoing de novo infection from mother to infant cells. Furthermore, a retrospective study showed that 8 of 38 infants born to STLV-1–infected mothers developed transient infection comparable to the cases above. Conclusions: Our findings demonstrate for the first time that spontaneous remission can occur after the establishment of retroviral MTCT. Our results unveil the unique dynamics of retroviral infection during MTCT.


  • Open Access

    Development of a novel multiplex digital PCR-based method for the detection of HTLV-1 proviral deletion

    by Kou Hiraga, Kenta Tezuka, Koh Nagata, Ki-Ryang Koh, Hitomi Nakamura, Yasuko Sagara, Rieko Sobata, Masahiro Satake, Michikazu Tanio, Hiroo Hasegawa, et al.


  • Open Access

    Highly homologous simian T-cell leukemia virus type 1 genome in Japanese macaques: a large cohort study

    by Kou Hiraga, Tomoya Kitamura, Madoka Kuramitsu, Megumi Murata, Kenta Tezuka, Kazu Okuma, Isao Hamaguchi, Hirofumi Akari, Takuo Mizukami

    Background: Simian T-cell leukemia virus type 1 (STLV-1) is a retrovirus closely related to human T-cell leukemia virus type 1 (HTLV-1), the causative agent of adult T-cell leukemia (ATL). It has been shown that Japanese macaques (Macaca fuscata, JMs) are one of the main hosts of STLV-1 and that a high percentage of JMs (up to 60%) are infected with STLV-1; however, the molecular epidemiology of STLV-1 in JMs has not been examined. Methods: In this study, we analyzed full-length STLV-1 genome sequences obtained from 5 independent troops including a total of 68 JMs. Results: The overall nucleotide heterogeneity was 4.7%, and the heterogeneity among the troops was 2.1%, irrespective of the formation of distinct subclusters in each troop. Moreover, the heterogeneity within each troop was extremely low (>99% genome homology) compared with cases of STLV-1 in African non-human primates as well as humans. It was previously reported that frequent G-to-A single-nucleotide variants (SNVs) occur in HTLV-1 proviral genomes in both ATL patients and HTLV-1 carriers, and that a G-to-A hypermutation is associated with the cellular antiviral restriction factor, Apobec3G. Surprisingly, these SNVs were scarcely observed in the STLV-1 genomes in JMs. Conclusions: Taken together, these results indicate that STLV-1 genomes in JMs are highly homologous, at least in part due to the lack of Apobec3G-dependent G-to-A hypermutation.


  • Open Access

    Establishment of a novel human T-cell leukemia virus type 1 infection model using cell-free virus

    by Koh Nagata, Kenta Tezuka, Madoka Kuramitsu, Naoki Fuchi, Yuri Hasegawa, Isao Hamaguchi, Kiyonori Miura

    Co-culture of infected and target cells is frequently used for studying HTLV-1 infection. Although this method efficiently infects HTLV-1, the cell mixture is complex, and it is extremely difficult to distinguish donor infected cells from target cells. In contrast, cell-free HTLV-1 infection models allow for more strict experimental conditions. In this study, we established a novel and efficient cell-free HTLV-1 infection model. Using this model, we successfully evaluated the infectivity titers of cell-free HTLV-1 as proviral loads (copies per 100 cells) in various cell lines, primary cultured cells, and a humanized mouse model. Interestingly, the HTLV-1-associated viral biofilms played an important role in enhancing the infectivity of the cell-free infection model. This cell-free HTLV-1 infection model reproduces the replication cycle of HTLV-1 and provides a simple, powerful, and alternative tool for researching HTLV-1 infection.


  • Open Access

    Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations

    by Madoka Kuramitsu, Haruka Momose, Yuichiro Uchida, Kenji Ishitsuka, Ryuji Kubota, Masahito Tokunaga, Atae Utsunomiya, Kunihiko Umekita, Yuuki Hashikura, Kisato Nosaka, et al.

    Antibody screening tests for human T-cell leukemia virus type 1 (HTLV-1) are performed based on methods such as chemiluminescent enzyme immunoassay (CLEIA), chemiluminescence immunoassay (CLIA), electrochemiluminescence immunoassay, and particle agglutination (PA). Espline HTLV-I/II, a commercially available, easy-to-use, and rapid immunochromatographic antibody test (IC), was developed for situations where expensive instruments and laboratory equipment are not available. In this report, we compared the performance of IC with the above existing tests using diverse samples derived from asymptomatic HTLV-1 carriers and patients with HTLV-1-associated diseases in collaboration with 11 Japanese institutes. We found that IC detected HTLV-1 infection in all samples from HTLV-1-associated diseases, including adult T-cell leukemia, HTLV-1-associated myelopathy, and HTLV-1 uveitis (200/200). The sensitivity of IC compared with CLIA, CLEIA, and PA was 99.2% (363/366), 100% (241/241), and 100% (47/47), respectively, and the specificity was 99.4% (994/1000), 100% (60/60), and 100% (40/40), respectively. The positive and negative predictive values of IC were 99.7% [95% confidence interval (CI): 99.12–99.92] and 99.5% (95% CI: 98.82–99.75), respectively. However, IC had difficulty in correctly judging samples that were diagnosed as seroreactive in other first screening tests but negative by a confirmatory test; for example, of 612 confirmed negative samples that were CLIA seroreactive, 332 samples were IC positive. These results confirmed that IC has sufficient sensitivity and specificity as a screening test for HTLV-1, although, like the other screening tests, it also requires a confirmatory test to determine HTLV-1 infection correctly. IMPORTANCE: The World Health Organization estimated that 5–10 million people are infected with human T-cell leukemia virus type 1 (HTLV-1). This number is likely to be underestimated because reliable endemic data are available for only approximately 1.5 billion people worldwide. The point-of-care test is a powerful tool for the easy and quick detection of infections without the requirement for expensive instruments and laboratory equipment. Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test that was evaluated in this study, might significantly advance our understanding of the global epidemiology of HTLV-1 infection.


  • HTLV-1 targets human placental trophoblasts in seropositive pregnant women

    by Kenta Tezuka, Naoki Fuchi, Kazu Okuma, Takashi Tsukiyama, Shoko Miura, Yuri Hasegawa, Ai Nagata, Nahoko Komatsu, Hiroo Hasegawa, Daisuke Sasaki, et al.

    Human T cell leukemia virus type 1 (HTLV-1) is mainly transmitted vertically through breast milk. The rate of mother-to-child transmission (MTCT) through formula feeding, although significantly lower than through breastfeeding, is approximately 2.4%–3.6%, suggesting the possibility of alternative transmission routes. MTCT of HTLV-1 might occur through the uterus, birth canal, or placental tissues; the latter is known as transplacental transmission. Here, we found that HTLV-1 proviral DNA was present in the placental villous tissues of the fetuses of nearly half of pregnant carriers and in a small number of cord blood samples. An RNA ISH assay showed that HTLV-1–expressing cells were present in nearly all subjects with HTLV-1–positive placental villous tissues, and their frequency was significantly higher in subjects with HTLV-1–positive cord blood samples. Furthermore, placental villous trophoblasts expressed HTLV-1 receptors and showed increased susceptibility to HTLV-1 infection. In addition, HTLV-1–infected trophoblasts expressed high levels of viral antigens and promoted the de novo infection of target T cells in a humanized mouse model. In summary, during pregnancy of HTLV-1 carriers, HTLV-1 was highly expressed in placental villous tissues, and villous trophoblasts showed high HTLV-1 sensitivity, suggesting that MTCT of HTLV-1 occurs through the placenta.


  • Development and evaluation of human T‐cell leukemia virus‐1 and ‐2 multiplex quantitative PCR

    by Madoka Kuramitsu, Kazu Okuma, Kenta Tezuka, Hitomi Nakamura, Yasuko Sagara, Ichiro Kurane, Isao Hamaguchi

    The diagnosis of human T ‐cell leukemia virus type 1 (HTLV‐1) infection in Japan is usually performed by serological testing, but the high rate of indeterminate results from western blotting makes it difficult to assess the infection accurately. Nucleic acid tests for HTLV‐1 and/or HTLV‐2 are used to confirm infection with HTLV‐1 and/or HTLV‐2 and are also used for the follow‐up of HTLV‐1 related diseases. To prepare a highly sensitive method that can discern infection with HTLV‐1 and HTLV‐2, a multiplex quantitative polymerase chain reaction (qPCR) by large‐scale primer screening was developed. Sensitivity and specificity were evaluated by serial dilution of cell lines and by testing with known clinical samples. The resulting multiplex qPCR can detect about four copies of HTLV‐1 provirus per 105 cells. Moreover, HTLV‐1 provirus could be detected in 97.2% (205 of 211) of HTLV‐1 seropositive clinical samples. These sensitivities were sufficiently high compared with the methods reported previously. Also, all the HTLV‐2 seropositive clinical samples tested were found to be positive by this method (three of three). In conclusion, this method can successfully and simultaneously detect both types of HTLV‐1 and HTLV‐2 provirus with extremely high sensitivity.